Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MAIA Biotechnology Inc. (MAIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MAIA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.13
1 Year Target Price $12.13
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.05% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.46M USD | Price to earnings Ratio - | 1Y Target Price 12.13 |
Price to earnings Ratio - | 1Y Target Price 12.13 | ||
Volume (30-day avg) 1 | Beta 0.04 | 52 Weeks Range 1.40 - 4.24 | Updated Date 06/29/2025 |
52 Weeks Range 1.40 - 4.24 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.96% | Return on Equity (TTM) -1131.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43600745 | Price to Sales(TTM) - |
Enterprise Value 43600745 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 30770600 | Shares Floating 25654231 |
Shares Outstanding 30770600 | Shares Floating 25654231 | ||
Percent Insiders 23.33 | Percent Institutions 4.88 |
Analyst Ratings
Rating 1 | Target Price 12.13 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MAIA Biotechnology Inc.
Company Overview
History and Background
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focusing on developing targeted cancer therapies. Founded with the goal of pioneering new cancer treatments, MAIA leverages its expertise in immuno-oncology and telomere biology to develop innovative therapeutics.
Core Business Areas
- Immuno-Oncology: Focuses on developing therapies that stimulate the patient's immune system to fight cancer, particularly using telomere-targeting agents.
- Drug Development: Involves preclinical and clinical studies of novel drug candidates for various cancer types.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, clinical research, and business management. Organizational structure includes departments for research and development, clinical operations, and corporate affairs.
Top Products and Market Share
Key Offerings
- THIO: THIO is MAIA's lead product candidate, a telomere-targeting agent being developed for solid tumors with telomere elongation. It is in Phase 2 clinical trials. Competitors include companies developing other telomere-targeting therapies and immuno-oncology drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in immuno-oncology, is rapidly growing with increasing demand for novel cancer therapies.
Positioning
MAIA is positioned as a clinical-stage company developing novel telomere-targeting therapies, focusing on niche cancer indications with high unmet needs. Its competitive advantage lies in its unique approach and early-stage clinical data.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be hundreds of billions of dollars. MAIA targets specific cancer subtypes, positioning it to capture a segment of this large market.
Upturn SWOT Analysis
Strengths
- Novel telomere-targeting technology
- Promising early-stage clinical data
- Experienced management team
- Focus on niche cancer indications
Weaknesses
- Limited financial resources
- Early-stage clinical development
- Dependence on single lead product candidate
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Increasing investor interest in immuno-oncology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- CRIS
- BNTX
- MRNA
- GILD
Competitive Landscape
MAIA's competitive advantage lies in its unique telomere-targeting approach, but faces competition from larger pharmaceutical companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Growth is dependent on advancement of its lead product candidate.
Future Projections: Future growth is highly dependent on the success of clinical trials and potential partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing the Phase 2 clinical trial of THIO and exploring potential collaborations.
Summary
MAIA Biotechnology is a clinical-stage biopharmaceutical company with a promising telomere-targeting technology, and is focused on cancer therapies. The company's future success hinges on its lead product candidate (THIO)'s advancement through clinical trials. The biggest challenges include financial constraints and intense competition in the cancer treatment market. Positive clinical results and strategic partnerships are critical for MAIA's growth. Investors should understand the high-risk nature of investing in clinical-stage biotech companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MAIA Biotechnology Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MAIA Biotechnology Inc.
Exchange NYSE MKT | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-07-28 | Co-Founder, President, CEO & Chairman of the Board of Directors Dr. Vlad Vitoc M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://maiabiotech.com |
Full time employees 13 | Website https://maiabiotech.com | ||
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.